Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $48.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 190.56% from the company’s previous close. A […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]
Rhenman & Partners Asset Management AB acquired a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 330,635 shares of the company’s stock, valued at approximately $5,733,000. Rhenman & Partners Asset Management AB […]
Leerink Partnrs Weighs in on Pliant Therapeutics, Inc s Q3 2023 Earnings (NASDAQ:PLRX) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.